Elvie Further Expands Access To Its Innovative Technology With Retail Launch Of Elvie Stride Plus

Based on consumer demand, Elvie is bringing its newest innovation to retailers across the country

Elvie, the revolutionary global femtech innovator, announces the launch of Elvie Stride Plus, featuring the award-winning breast pump, Elvie Stride, along with a 3-in-1 Carry Bag.

Elvie Stride Plus will provide more women access to its innovative breast pumping solutions. The waitlist opens today, March 21, and Elvie Stride Plus will be available to order on April 20 on Elvie.com. This announcement follows the successful Elvie Stride launch into the healthcare channel in 2021, which sold out within two weeks of launch.

Elvie Stride Plus is a hands-free, hospital-grade electric breast pump, with 3-in-1 Carry Bag. This award-winning breast pump connects to the Pump with Elvie app and allows users to track their pumping history and control the pump from their phone. The 3-in-1 Carry Bag comes with a wet bag for mess-free travel, a cool bag and an ice pack to keep breast milk fresh. The bag is also compatible with standard 5 oz milk storage bottles and bags (sold separately). Previously, Elvie Stride was only available through insurance; now consumers have the opportunity to purchase this game-changing breast pump at Elvie.com.

“When we launched Elvie Stride six months ago, we were thrilled to hear women rave about how Elvie Stride changed their lives through its technology and performance, especially for the value and during a time when women are taking on so much more responsibility,” said Tania Boler, founder, and CEO of Elvie. “We know how challenging it is to find high-performing products packaged all together. By creating an all-inclusive carrying system and offering it for purchase directly, we’re one step closer to filling the innovation gap in technology for women.”

Elvie continues to expand its product line and innovate new solutions for more women to have access to products that work smarter and harder for their bodies. Elvie’s category leadership has been recognized by industry titans; most recently, Elvie Stride won the 2021 TIME Best Invention Award for its product design, innovation and accessibility. The new launch follows Elvie’s latest campaign, Smart Bodies, unveiled on International Women’s Day. Featuring multi-genre artist Eva Lazarus, the campaign celebrates women’s bodies for their complexities beyond their aesthetic value and highlights how Elvie is providing women with the technology their bodies deserve. More here.


Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy